Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer

应用分子和功能基因组学来识别诊断和治疗癌症的生物标志物

• 批准号: 10249257
• 负责人: Kiranmai Gumireddy
• 金额: $ 13.82万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-16 至 2021-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249257
• 关键词: Adoption; Area; Award; Bioinformatics; Biological Assay; Biological Markers; Biopsy; Cancer Patient; Cells; Cellular biology; Clinical; Collaborations; Diagnosis; Ensure; Funding; Gene Expression Profile; Genomics; Glioblastoma; Goals; Individual; Industry; Journals; Knowledge; Legal patent; Malignant Neoplasms; Malignant neoplasm of lung; Methods; Molecular; Molecular Biology; Molecular Biology Techniques; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Paper; Patients; Peripheral Blood Mononuclear Cell; Plasma; Protocols documentation; Publications; Publishing; RNA; RNA Editing; Research; Research Personnel; Research Project Grants; Risk; Role; Sampling; Screening for cancer; Specialist; T cell receptor repertoire sequencing; Techniques; Technology; The Wistar Institute; Translational Research; Tumor Antigens; Work; base; biobank; biomarker signature; blood-based biomarker; career; circulating biomarkers; design; effective therapy; experience; functional genomics; genetic signature; genomic data; improved; interest; nano-string; novel; operation; personalized medicine; success; tumorigenesis

SUMMARY This application will support an exceptional Research Specialist who is essential to the scientific direction, operation, and enhancement of a productive research group. The Research Specialist and Unit Director have worked together since 2009, closely since 2017. The major goal of the Unit Director’s group is to develop inexpensive, non-invasive methods that can identify individuals who are at risk of non-small cell lung cancer and use the information obtained to improve therapy. As part of this effort, the Research Specialist is responsible for collecting and maintaining The Wistar Institute biorepository of 3,350 non-small cell lung cancer patient samples, including PBMC, PAXgene, and plasma. The Director’s group also manages Genomics and Bioinformatics Cores, which support ~15 NCI-funded research projects. Last, the Unit Director and Research Specialist collaborate with other Wistar investigators and industry to: identify a gene expression signature that can subclassify glioblastoma, characterize a potential new tumor antigen generated by the fusion of 2 LNC- RNAs, and understand the role of A-to-I RNA editing in metastasis. The Research Specialist has expertise in cell and molecular biology and extensive experience in multiple genomics and cell biology techniques. She also has a strong interest in translational research and has been able to apply the knowledge generated to design more effective therapies for lung cancer and glioblastoma. She is first author on 17 of the 26 papers she has published and on 9 of the 17 papers published during her 12-year tenure at Wistar. Many are in highly ranked journals including Nature Cell Biology, PNAS, EMBO, and Cell. She is listed on 5 U.S. patents. The Research Specialist’s expertise in a wide variety of molecular biology techniques is critical for the success of all main projects. It makes her ideally suited to conduct the studies on developing lung cancer genetic and biomarker signatures using genomic based assays; it also enables her to identify areas where improvements/changes are needed and independently develop protocols to improve the variety of assays employed. Since the Showe lab has been the primary developer of new genomics technologies for adoption by the Genomics Core, the Research Specialist’s background is essential for being able to develop these new platforms, including TCR-seq, the assessment of various platforms for single cell genomics, and the implementation of various NanoString technologies. For most work, the Research Specialist is the primary interface with Bioinformatics, ensuring that genomic data is correctly interpreted for analysis. The Research Specialist is essential not only for completing the proposed work of the next five years, but also for identifying new directions and new research and clinical collaborations. In summary, this award will allow the Research Specialist to continue making significant contributions to identifying circulating biomarkers for early cancer detection and to understanding the mechanisms of metastasis and oncogenesis. It will advance the identification of circulating biomarkers for lung cancer, support multiple NCI-funded groups via the Genomics Core, and enhance novel collaborations.

摘要 该应用程序将支持一位对科学方向至关重要的杰出研究专家， 运作，并加强一个富有成效的研究小组。研究专家和单位主任 自2009年以来一直合作，自2017年以来一直密切合作。股长小组的主要目标是发展 廉价、非侵入性的方法，可以识别有患非小细胞肺癌风险的个人，并 使用所获得的信息来改进治疗。作为这项工作的一部分，研究专家负责 收集和维护Wistar研究所3350例非小细胞肺癌患者的生物库 样本包括PBMC、PAX基因和血浆。主任的小组还管理基因组学和 生物信息学核心，支持约15个NCI资助的研究项目。最后，单位主任和研究 专家与其他Wistar研究人员和行业合作：识别 可以对胶质母细胞瘤进行亚型分类，鉴定一种潜在的新的肿瘤抗原，该抗原是由2个LNC- RNA，并了解A-to-I RNA编辑在转移中的作用。研究专家具有以下专业知识 细胞和分子生物学，以及在多种基因组学和细胞生物学技术方面的丰富经验。她还 对翻译研究有浓厚的兴趣，并能够将所产生的知识应用于设计 对肺癌和胶质母细胞瘤更有效的治疗方法。她的26篇论文中有17篇是第一作者 在她12年的维斯塔尔任期内，发表了17篇论文中的9篇。许多人排名靠前 期刊包括自然细胞生物学、PNAS、EMBO和细胞。她被列入了5项美国专利。研究报告 专家在各种分子生物学技术方面的专业知识是所有主要技术成功的关键 项目。这使她成为开展肺癌基因和生物标志物研究的理想人选。 使用基于基因组的分析进行签名；这也使她能够识别哪些方面需要改进/更改 需要并独立开发方案，以改进所采用的各种分析方法。自从Showe实验室 一直是基因组学核心研究所采用的新基因组学技术的主要开发者 专家的背景对于能够开发这些新平台是至关重要的，包括TCR-seq、 单细胞基因组学各种平台的评估，以及各种纳米串的实现 技术。对于大多数工作，研究专家是生物信息学的主要接口，确保 基因组数据被正确地解释用于分析。研究专家不仅对完成 未来五年的拟议工作，也是为了确定新的方向和新的研究和临床 合作。总而言之，这一奖项将允许研究专家继续做出有意义的 有助于识别用于癌症早期检测的循环生物标志物，并有助于理解 转移和肿瘤发生的机制。这将促进肺循环生物标志物的鉴定。 通过基因组学核心支持多个由NCI资助的团体，并加强新的合作。